Healthy
Conditions
Keywords
asimadoline, pharmacokinetic, excretion of 14C-derived radioactivity, metabolite profile, 14C-asimadoline, metabolites, single and multiple oral doses
Brief summary
This is an open label, single center, metabolite identification, mass balance, and PK study in healthy male volunteers.
Detailed description
This is an open label, single center, metabolite identification, mass balance, and PK study in healthy male volunteers. The purposes of this study is to determine the excretion of total \[14C\] derived radioactivity and the metabolite profile after a single oral dose of \[14C\] asimadoline as well as to identify and quantitate the metabolites of asimadoline in plasma, urine, and feces after single and multiple oral doses of asimadoline.
Interventions
DRUGasimadoline
10mg \[14\]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
Sponsors
Tioga Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 56 Years
Healthy volunteers
Yes
Inclusion criteria
* Be informed of the nature of the study and have provided written informed voluntary consent * Be healthy males, at least 18 years of age or the legal age of consent (whichever is greater) and less than 56 years of age * Have a body mass index (BMI) \>=18.0 and \<32.0 kg/m2 and weigh at least 50 kg * Be in good general health with no clinically relevant abnormalities based on the medical history, physical examination, clinical laboratory evaluations (hematology, clinical chemistry, urinalysis), and 12 lead electrocardiogram (ECG) that, in the opinion of the Investigator, would affect subject safety * Agree to comply with the study procedures and restrictions.
Exclusion criteria
* Any disease or condition that might affect drug absorption, metabolism, or excretion, or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease * Receipt of a radioisotope with an effective half-life of 30 days or more within the previous 12 months * Receipt of any diagnostic radiation procedures with an effective dose exceeding 1 rem in their lifetime * Occupational exposure to radiation (e.g., those routinely required to wear a radiation monitoring badge) * Receipt of any radiation treatments/therapy * History of constipation or infrequent bowel movements (\<=6 bowel movements per week on average) * Known or suspected hypersensitivity or allergic reaction to asimadoline or similar chemical compounds or any of the components of asimadoline tablets * Chronic use of any systemic medications (with the exception of vitamins taken at standard supplement doses); use of a drug therapy (including herbal preparations, e.g., St. John's wort) known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study medication; use of prescription medication within 14 days before administration of study medication or over-the-counter products (including natural products) within 7 days before administration of study medication, except for topical products without systemic absorption, unless approved by the Sponsor * Have smoked cigarettes or used nicotine-containing products over the last 3 months and not able to abstain from smoking for the duration of the confinement period * If not sterile, cannot agree to use one of the following approved methods of contraception, from check-in until 3 months following Study Completion/Clinic Discharge: a male condom with spermicide; a sterile sexual partner; use by a female sexual partner of an intrauterine device with spermicide; a female condom with spermicide; contraceptive sponge with spermicide; a cervical cap with spermicide; or oral, implantable, transdermal, or injectable contraceptives with a reliable secondary back-up method * Current history or evidence of drug or alcohol abuse or a positive screen for substances of abuse or alcohol at screening or admission * Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody * Receipt of an investigational product or device, or participation in a drug research study within a period of 30 days (or 5 half lives of the drug, whichever is longer) before the first dose of study medication * Blood loss or blood donation of \>550 mL within 90 days or plasma donation \>500 mL within 30 days before administration of study drug * Any food allergy, intolerance, restriction, or special diet that, in the opinion of the Investigator, should preclude the subject's participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of [14C]derived radioactivity in urine and feces after a single oral dose of [14C]asimadoline | up to 1 month |
| Concentration of metabolites of asimadoline in plasma, urine, and feces after single and multiple oral doses of asimadoline. | up to 1 month |
Secondary
| Measure | Time frame |
|---|---|
| Determination of plasma pharmacokinetics (e.g., Cmax, AUC, tmax, t1/2) of asimadoline and major metabolites | up to 1 month |
| Number of subjects with adverse events | up to 1 month |
Countries
United States
Outcome results
None listed